<unk>  is indicated for the treatment of major depressive disorder and neuropathic pain and for the prevention of migraine and chronic tension headache. It can be used for the treatment of nocturnal enuresis in children older than 6 after other treatments have failed. Depression<unk>  is effective for depression, but it is rarely used as a first-line antidepressant due to its higher toxicity in overdose and generally poorer tolerability. It can be tried for depression as a second-line therapy, after the failure of other treatments. For treatment-resistant adolescent depression or for cancer-related depression<unk>  is no better than placebo. It is sometimes used for the treatment of depression in Parkinson disease, but supporting evidence for that is lacking. Pain<unk>  alleviates painful diabetic neuropathy. It is recommended by a variety of guidelines as a first or second line treatment. It is as effective for this indication as gabapentin or pregabalin but less well tolerated. Low doses of<unk>  moderately improve sleep disturbances and reduce pain and fatigue associated with fibromyalgia. It is recommended for fibromyalgia accompanied by depression by Association of the Scientific Medical Societies in Germany and as a second-line option for fibromyalgia, with exercise being the first line option, by European League Against Rheumatism. Combinations of<unk>  and fluoxetine or melatonin may reduce fibromyalgia pain better than either medication alone. There is some (low-quality) evidence that<unk>  may reduce pain in cancer patients. It is recommended only as a second line therapy for non-chemotherapy-induced neuropathic or mixed neuropathic pain, if opioids did not provide the desired effect. Moderate evidence exists in favor of<unk>  use for atypical facial pain.<unk>  is ineffective for HIV-associated neuropathy. Headache<unk>  is probably effective for the prevention of periodic migraine in adults.<unk>  is similar in efficacy to venlafaxine and topiramate but carries a higher burden of adverse effects than topiramate. For many patients, even very small doses of<unk>  are helpful, which may allow for minimization of side effects.<unk>  is not significantly different from placebo when used for the prevention of migraine in children.<unk>  may reduce the frequency and duration of chronic tension headache, but it is associated with worse adverse effects than mirtazapine. Overall,<unk>  is recommended for tension headache prophylaxis, along with lifestyle advice, which should include avoidance of analgesia and caffeine. Other indications<unk>  is effective for the treatment of irritable bowel syndrome; however, because of its side effects, it should be reserved for select patients for whom other agents do not work. There is insufficient evidence to support its use for abdominal pain in children with functional gastrointestinal disorders. Tricyclic antidepressants decrease the frequency, severity, and duration of cyclic vomiting syndrome episodes.<unk> , as the most commonly used of them, is recommended as a first-line agent for its therapy.<unk>  may improve pain and urgency intensity associated with bladder pain syndrome and can be used in the management of this syndrome.<unk>  can be used in the treatment of nocturnal enuresis in children. However, its effect is not sustained after the treatment ends. Alarm therapy gives better short- and long-term results. In the US,<unk>  is commonly used in children with ADHD as an adjunct to stimulant medications without any evidence or guideline supporting this practice. Many physicians in the UK (and the US also) commonly prescribe<unk>  for insomnia; however, Cochrane reviewers were not able to find any randomized controlled studies that would support or refute this practice.
Amitriptyline
Nortriptyline
Venlafaxine
Trazodone
Guanfacine
Nabilone
Citalopram
Atomoxetine